C oronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are both used for myocardial revascularization in patients with complex coronary artery disease (CAD) with an indication for revascularization (1) . A large number of studies have reported or compared outcomes of CABG and PCI as optimum treatment strategies (2) , but data are limited on the causes, circumstances, and the mechanisms of death after these procedures.
Observational studies have reported causes of death after PCI and CABG (3) (4) (5) 
METHODS STUDY DESIGN, PATIENTS, AND RANDOMIZATION.
The design, methods, and procedural details of the SYNTAX trial have been reported previously (7) (8) (9) .
The SYNTAX study was a prospective, multinational, randomized trial conducted in 85 centers in the United States and Europe. In this study, 1,800 patients with de novo left main (LM) or 3-vessel disease (3VD) were randomly assigned to undergo CABG or PCI with first-generation paclitaxel-eluting stents (Taxus Express, Boston Scientific, Natick, Massachusetts). Association treatment guidelines (11, 12) was strongly recommended for all patients. Medication use for the randomized cohort was collected at baseline, discharge, at 1 and 6 months, and at 1, 3, and 5 years post-allocation. For the nested registries, this was collected at baseline and discharge.
This study was done in accordance with the principles of the Declaration of Helsinki, and all sitespecific institutional review boards and applicable regulatory agencies approved the study protocol before study initiation.
DEFINITIONS. The definitions used for the classifications of adverse events have been previously reported elsewhere (9) . Mortality data during the course of follow-up were collected prospectively. forwarded to the independent CEC, including the death certificates, the coroner's report, and other records (hospital discharge summary, pathology, laboratory, radiology, and other diagnostic data). The CEC was composed of physicians who were experts in cardiology, cardiac surgery, and neurology. Two CEC members reviewed all deaths independently in a blinded manner. Disagreements between reviewers and principal investigators were discussed and resolved by full CEC consensus.
Because the SYNTAX study began before publication of the Academic Research Consortium definition (13) , it used specially designed definitions of death.
The CEC classified deaths into cardiovascular or noncardiovascular, according to the trial protocol. Cardiovascular deaths were further classified as cardiac (sudden cardiac deaths, myocardial infarction [MI], progressive heart failure, and arrhythmia) and cardiac others (which included other cardiac causes, e.g., cardiac tamponade and cardiac deaths with insufficient information for definitive classification), vascular (stroke, aortic dissection, and pulmonary embolism), and vascular others (major hemorrhage, peripheral embolism, and other). Using these classifications, the following cardiac subgroups were defined and analyzed: 1) sudden cardiac deaths; 2) MI-related deaths; and 3) congestive heart failure (CHF), arrhythmia, and all other cardiac deaths, the latter of which were combined together into a single subgroup because of the low number of cases in each particular subgroup. Noncardiovascular deaths included those resulting from chronic respiratory disease, pneumonia, malignancy, diabetes mellitus, and other conditions (which included infections, accidents, suicides, trauma-related, chronic disease, and others).
When a specific cause of death could not be determined from the available evidence, the death was classified as undetermined. Every death was attributed to one of the specific causes exclusively.
Major adverse events were considered nonfatal if no death occurred within 30 days of the event, and when it was not possible to establish any association between the event and death from the narrative description of death.
During the Heart Team meeting, both the interventional cardiologist and surgeon documented which vessels that were $1.5 mm diameter and >50% stenosis needed revascularization. In the original trial protocol, incomplete revascularization was defined when the actual revascularization did not correlate with this pre-operative Heart Team statement.
STATISTICAL ANALYSES. All analyses in the randomized cohort were done according to the intention-to-treat principle, whereas in the nested registries, outcomes were presented according to the as-treated principle. As previously described, no statistical comparisons between the PCI and CABG registries were performed (10).
Continuous variables were reported as mean AE SD and compared with the Student t test. Binary variables were expressed as counts and/or percentages and compared with the chi-square test or Fisher exact test, as appropriate. Five-year rates of death were estimated using the Kaplan-Meier method, and comparisons between PCI and CABG were done using the log-rank test. For the randomized cohort, subgroup analyses were performed for pre-specified groups of patients with LM or 3VD and diabetic pa- Schoenfeld residuals (14) . There was no evidence of departure from the assumption of proportionality.
Multivariate analyses were performed using Cox proportional hazard models with backward selection of variables to construct a set of independent predictors. Variables considered of clinical importance and with a p value <0.15 in univariate analysis were considered in the multivariate models (Online Appendix). Models were constructed for the overall randomized cohort and CABG and PCI randomized groups separately, as well as for the PCI and CABG registry patients separately. The performance of the models was tested using receiver-operating characteristics curves. A 2-sided p value of <0.05 was considered to be statistically significant for all tests.
Analyses were performed using SPSS version 20.0 statistical software (IBM, Armonk, New York).
RESULTS

CAUSES OF DEATH.
During the 5-year follow-up, there were 123 deaths after PCI and 97 deaths after CABG in the randomized cohort. Among PCI patients, the majority of deaths were cardiovascular (67.5%, n ¼ 83), of which nearly all deaths were from cardiac causes ( Table 1 ). The largest cause of cardiovascular death after PCI was related to MI ( Figure 1A ). In the CABG group, cardiovascular deaths accounted for (n ¼ 47), and 2.1% (n ¼ 2) of deaths occurred due to undetermined causes ( Table 1) . Of cardiovascular death, only a few deaths were from vascular causes.
The greatest cause of cardiovascular death after CABG was CHF, arrhythmia, or other causes ( Figure 1A ).
In the PCI registry, 22 (38.6%) patients died of cardiovascular causes, and the majority of deaths (50.9%, n ¼ 33) were due to noncardiovascular causes Rates of all-cause death at 5-year follow-up were 30.0% (n ¼ 57) in the PCI registry and 12.6% (n ¼ 79) in the CABG registry ( Table 1) . Specific causes of death are shown in Figure 3 . Figure 4C ). In CABG patients, there was no increased risk in any specific causes of death associated with incomplete revascularization ( Figure 4C ).
PATIENT CHARACTERISTICS AND PREDICTORS OF
ALL-CAUSE AND CARDIAC DEATH. R a n d o m i z e d t r i a l . Significant baseline and lesion characteristics of patients who were alive or dead at 5 years after revascularization are summarized in Table 2 (complete results are in the Online Table 1 ). Patients who died after both PCI or CABG had a higher risk profile at baseline than those who were still alive; they were older, had a higher presence of co-morbidities (diabetes, peripheral vascular disease, chronic obstructive pulmonary disease, carotid artery disease, and creatinine >200 mmol/l), which resulted in higher EuroSCORE values. Moreover, rates of medically treated diabetes and the mean SYNTAX score were significantly higher in patients who died after PCI, but these rates were not higher in patients who died after CABG.
In multivariate analysis, PCI versus CABG treatment was not an independent predictor of all-cause death.
Although, in the overall model, as well as in the separate PCI and CABG models, numerous baseline variables, such as older age and the presence of comorbidities, were independent predictors ( Table 3) .
Moreover, procedural events such as incomplete revascularization, post-procedural prescription of medication as secondary prevention, and the occurrence of nonfatal adverse events were predictive of all-cause death. In separate models, results were largely similar, although incomplete revascularization, medically treated diabetes and left ventricular function were only predictors in the PCI model and not in the CABG model ( Table 3) . In contrast, renal failure and chronic obstructive pulmonary disease were only predictors in the CABG model. Milojevic et al.
Cause of Death in the SYNTAX Trial
Treatment with PCI versus CABG was an independent predictor of cardiac death (HR: 1.55; 95%
CI: 1.0 to 2.33; p ¼ 0.045) ( Table 4) . Furthermore, the independent predictors in the overall and PCI models for cardiac death were nearly identical as for all-cause death ( Table 4 ). An additional predictor for cardiac events after PCI was the SYNTAX score.
The CABG model included previous MI and bypass time as additional independent predictors, whereas other baseline characteristics no longer were predictors.
N e s t e d r e g i s t r i e s . Baseline and procedural characteristics of patients alive at the end of follow-up and patients who died during follow-up are reported in the Online Table 2 . In the multivariate models that predicted all-cause and cardiac death, results were relatively similar to the randomized cohort, with a number of baseline, procedural, and post-procedural Non-CVD ¼ noncardiovascular; UNK ¼ unknown/undetermined; other abbreviations as in Figure 1 .
Cause of Death in the SYNTAX Trial variables as independent predictors ( Table 5) . Of note, in the PCI registry, LM disease and the SYNTAX score were predictors.
DISCUSSION
The present study provides crucial perspectives on causes of death within the SYNTAX trial at 5-year follow-up (Central Illustration). Our findings indicate that treatment with CABG significantly reduces cardiac death compared with PCI, which was due exclusively to a lower incidence of MI-related death.
Particularly in patient groups with 3VD and/or a SYNTAX score $33, cardiac death was significantly higher after PCI than CABG. Numerous patient baseline characteristics were independent predictors of death, although procedural characteristics (e.g., incomplete revascularization), the use of specific medications, and events during follow-up (e.g., nonfatal MI) also contributed in predicting all-cause and cardiac death.
Similarly to previous randomized trials that compared CABG with PCI using bare-metal stents, long-term rates of all-cause mortality were comparable between CABG and PCI (15, 16) . sudden cardiac deaths, in which there was no difference in the rate of sudden cardiac death after CABG versus PCI (19) .
In the present analysis, there was a significant difference in rates of cardiac death between CABG and PCI. Rates of sudden cardiac death were comparable, but MI-related deaths were significantly lower after CABG. The majority of deaths among patients who underwent PCI were related to MI, which accounted for nearly 50% of the total cardiac deaths.
In the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial, the reduction in the Values are n (%) or mean AE SD.
ARB ¼ angiotensin receptor blocker; ACE ¼ angiotensin-converting enzyme; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; other abbreviations as in Table 1 .
underwent PCI can progress to cause MI and subsequently death, whereas after CABG, the significance of such lesions with an existing patent bypass graft is limited. Even with the use of second-generation DES, the rate of spontaneous MI continues to be higher after PCI than CABG (25) . Moreover, the lower rates of MI-related deaths with CABG might result from more complete revascularization and subsequently lower areas of ischemic myocardium (6, 26) . These concepts were validated in several studies that demonstrated that CABG had more durable protection against MI in patients with extensive CAD (16, 27, 28) .
Because incomplete revascularization with PCI occurs more often in patients with highly complex lesions, and specifically chronic total occlusions (26, 29) , the present results emphasize these differences between CABG and PCI in the cardiac death subgroup analyses according to SYNTAX score tertiles. In the highest SYNTAX score tertiles, patients who underwent PCI had a higher risk of MI-related death and sudden cardiac deaths. Patients with complex disease undergoing PCI have a continued higher risk of stent thrombosis, which is related to cardiac death (30) . In patients with complex disease and incomplete revascularization, lesions without revascularization have a considerable risk of progressing to acute events, a similar finding as in an analysis of the BARI trial that showed that revascularization versus no revascularization reduced the rate of sudden cardiac death (6) . Moreover, progression of disease in patients with complex disease and higher SYNTAX scores may be enhanced because Abbreviations as in Tables 1 to 3 . In subgroups according to diabetes, the difference between PCI and CABG in cardiac death was greater in diabetic patients than in nondiabetic patients, whereas the difference in all-cause death was not significant in diabetic patients (32) . This is notable in the BARI publication ( Team should not only determine the most optimal Tables 1 to 3. revascularization strategy, but which strategy might also be useful when integrated into the postprocedural phase (7).
STUDY LIMITATIONS. The present study represents a post-hoc analysis; therefore, the results should be regarded as exploratory and hypothesis-generating.
Moreover, a great number of subgroup analyses have been reported, so results should be interpreted with caution because some differences may be the results of chance (42). Although the SYNTAX trial was an all-comers randomized trial, inclusion of patients in a randomized trial is limited to specific inclusion and exclusion criteria; therefore, the external validity, which reflects actual patients in the real-world, may be suboptimal.
Despite the primarily used SYNTAX trial classifications, the determination of cause-specific death could not always be established. This is particularly relevant to the subcategories of cardiac death in which absolute precision may not always be possible.
However, bias was limited by event adjudication by a blinded committee of physician experts using previous standardized definitions.
Autopsy was performed in a low number of cases (n ¼ 38, 10.7%); therefore, the rate of death related to MI could be underestimated, considering that MI might be involved in the process of heart failure and cardiac rupture, as well as sudden cardiac death.
We did not have information on post-procedural occurrence of additional co-morbidities, which could affect the established groups of predictors.
Although medication use was recorded throughout different time points during follow-up, there were no data on compliance rates or on reasons for After percutaneous coronary intervention (PCI), the leading cause of cardiovascular death was myocardial infarction (MI)-related death. After coronary artery bypass grafting (CABG), the leading cause of cardiovascular death was congestive heart failure (CHF), arrhythmia, or other causes (e.g., arrhythmia and all other cardiac deaths).
J A C C V O L . 6 7 , N O . 1 , 2 0 1 6 discontinuation of medication. Moreover, at later follow-up with longer periods between collection of medication data (e.g., 2 years), we were unable to determine the exact date of medication discontinuation. Therefore, we could not assess the impact of medication use during follow-up on death rates. 
CONCLUSIONS
